Phaseline

Companies › Buzzard Pharmaceuticals

Buzzard Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
isunakinra
IL-1 receptor 1 inhibitor
IL1R1Phase 2Colorectal Cancer Metastatic; Triple-Negative Breast Cancer (TNBC)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06634875isunakinraPhase 2Colorectal Cancer MetastaticOncologyJun 2027
NCT07698106isunakinraPhase 1Triple-Negative Breast Cancer (TNBC)OncologyAug 2034

Targets

IL1R1 (1)

Companies with the same targets

Swedish Orphan Biovitrum

Companies built like this

Cellvax Therapeutics Spectrum Pharmaceuticals Newish Technology (Beijing) BrainChild Bio TVAX Biomedical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.